Media Centre
Latest press releases
-
Tagrisso with the addition of chemotherapy showed favourable trend in overall survival in EGFR-mutated advanced lung cancer with further follow up in FLAURA2 Phase III trial
-
AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer
-
Lynparza and Imfinzi demonstrated strong clinical benefit and more than doubled median duration of response vs. chemotherapy in patients with mismatch repair proficient advanced or recurrent endometrial cancer
-
AstraZeneca to acquire Amolyt Pharma, expanding late-stage rare disease pipeline
-
Two datopotamab deruxtecan applications validated in the EU for patients with advanced nonsquamous non-small cell lung cancer or HR-positive, HER2-negative breast cancer
Medical Releases
These press releases are specifically for health specialist/medical media and are not for consumer press.
